J. Monk

发表

Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

P. A. Todd, J. Monk, 1987 .

Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay

T. Olencki, G. Lesinski, D. Benson, 2008, Cancer Immunology, Immunotherapy.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK–STAT Signal Transduction in Human Immune Cells

Amanda R. Campbell, M. Caligiuri, J. Byrd, 2008, The Journal of Immunology.

Multiparametric Flow Cytometric Analysis of Signal Transducer and Activator of Transcription 5 Phosphorylation in Immune Cell Subsets In vitro and following Interleukin-2 Immunotherapy

T. Olencki, G. Lesinski, W. Carson, 2006, Clinical Cancer Research.

Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

J. Monk, J. Henwood, 1988, Drugs.

High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review.

W. Rathmell, J. Monk, 2008, Urology.

A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors

M. Grever, Xin Wu, Y. Yen, 2013, Investigational New Drugs.

A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401.

P. Kantoff, M. Morris, E. Small, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sufentanil

R. Beresford, J. Monk, A. Ward, 2012, Drugs.

Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

P. A. Todd, J. Monk, 1987, Drugs.

Erratum to A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in the Treatment of Arrhythmias

R. N. Brogden, J. Monk, 1991, Drugs.

Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

R. N. Brogden, J. Monk, 1990, Drugs.

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

I. Thompson, C. Tangen, M. Carducci, 2018, Cancer treatment and research communications.

Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma

B. Rovin, T. Nadasdy, A. Satoskar, 2007, Nature Clinical Practice Nephrology.

Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma.

E. Lam, T. Olencki, G. Lesinski, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

T. Lackner, J. Monk, D. Campoli-Richards, 1987, Drugs.

Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses.

R. N. Brogden, J. Monk, 1991, Drugs.

Colloidal Bismuth Subcitrate

P. Benfield, A. Wagstaff, J. Monk, 1988, Drugs.

Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.

R. Heel, J. Monk, 1987, Drugs.

Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

P. Benfield, A Ward, D M Campoli-Richards, 1988, Drugs.

Enprostil

K. Goa, J. Monk, K. Goa, 1987, Drugs.

Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

J. Monk, D. Campoli-Richards, 1987, Drugs.

Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

J. Monk, J. Henwood, 1988, Drugs.

A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use

J. Monk, D. Campoli-Richards, Deborah M. Campoli-Richards, 2012 .

Misoprostol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.

S. Clissold, J. Monk, 1987, Drugs.

Inhaled Pentamidine

P. Benfield, J. Monk, 1990, Drugs.

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.

J. Eastham, M. Gleave, H. Beltran, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

A. Ellrodt, M. S. Langley, E. Saltiel, 1988, Drugs.

Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer

M. Wing, Russell Bonneville, Hui-Zi Chen, 2019, Prostate Cancer and Prostatic Diseases.

Consumption of dietary supplements and over-the-counter and prescription medications in men participating in the Prostate Cancer Prevention Trial at an academic center.

S. Lemeshow, R. Bahnson, S. Clinton, 2008, Urologic oncology.

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

F. Saad, M. Morris, E. Small, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

P. Kantoff, M. Morris, E. Small, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

I. Thompson, C. Tangen, N. Agarwal, 2013, The Lancet. Oncology.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

I. Thompson, C. Tangen, L. Fink, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approach.

Vipul R Patel, V. Patel, D. Benson, 2007, Urology.

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial

Y. Tai, I. Thompson, C. Tangen, 2015, International journal of cancer.

Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

P. Benfield, A. Wagstaff, J. Monk, 1988, Drugs.

Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.

M. Caligiuri, G. Phillips, G. Otterson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anisoylated Plasminogen Streptokinase Activator Complex (APSAC)

R. Heel, J. Monk, 1987, Drugs.

SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC).

I. Thompson, C. Tangen, N. Agarwal, 2012 .

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

E. Heath, P. Mack, A. Hussain, 2019, The oncologist.

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer

P. Kantoff, M. Morris, E. Small, 2013, Cancer.

A Combination of Tomato and Soy Products for Men With Recurring Prostate Cancer and Rising Prostate Specific Antigen

R. Bahnson, A. Ferketich, S. Clinton, 2008, Nutrition and cancer.

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy

E. Small, J. Picus, N. Vogelzang, 2012, Cancer.

Information Seeking and Satisfaction With Physician–Patient Communication Among Prostate Cancer Survivors

R. Bahnson, Prabu David, D. Cegala, 2008, Health communication.

Effects of a lifestyle intervention on body composition in prostate cancer patients on androgen deprivation therapy

C. Fairman, B. Focht, J. Thomas-Ahner, 2020, JCSM clinical reports.

Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.

J P Monk, S Titmarsh, J. Monk, 1987, Drugs.

Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the bladder: A single-institution experience.

T. Olencki, R. Bahnson, A. Shabsigh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer

Wei Chen, J. Datta, R. Goldberg, 2017, Oncotarget.

LBA-12 CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER

J. Eastham, M. Gleave, H. Beltran, 2019, Journal of Urology.

Effects of a Group-Mediated Exercise and Dietary Intervention in the Treatment of Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Results From the IDEA-P Trial.

C. Fairman, B. Focht, J. Thomas-Ahner, 2018, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).

P. Kantoff, M. Morris, E. Small, 2012 .

Inhaled pentamidine. An overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia.

P. Benfield, J. Monk, 1990, Drugs.

Chemotherapy for the initial treatment of metastatic prostate adenocarcinoma and neuroendocrine carcinoma at diagnosis: real world application and impact in the SEER database (2004 –2018)

M. Yin, S. Clinton, C. Tsao, 2023, Frontiers in Oncology.

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors

G. Otterson, M. Villalona-Calero, M. Hensley, 2012, Investigational New Drugs.

Real-Time Scintigraphic Assessment of Intravenous Radium-223 Administration for Quality Control

N. Hall, C. Wright, D. Murrey, 2015, BioMed research international.

Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognotic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC).

Y. Tai, I. Thompson, C. Tangen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

J. Monk, D. Campoli-Richards, 1987, Drugs.

Sufentanil. A review of its pharmacological properties and therapeutic use.

R. Beresford, J. Monk, A. Ward, 1988, Drugs.

Bevacizumab in metastatic papillary renal cell carcinoma (PRCC).

T. Olencki, D. Zynger, A. Mortazavi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451).

A. Hussain, U. Vaishampayan, T. Flaig, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Misoprostol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.

S. Clissold, J. Monk, 1987, Drugs.